PDCD1 and non-small cell lung carcinoma: Between September 4, 2020, and July 12, 2021, a total of 40 patients with advanced NSCLC, who had previously been treated with platinum-doublet chemotherapy and ICIs (anti-PD-1 or anti-PD-L1) and progressed after ≤ 2 lines of systemic therapy, were enrolled in cohort 7 from 12 study centers in China.